

To: The Honorable Joseph Biden  
President of the United States

The Honorable Xavier Becerra  
Secretary of Health and Human Services

The Honorable Nancy Pelosi  
Speaker

The Honorable Kevin McCarthy  
House Republican Leader

The Honorable Chuck Schumer  
Senate Majority Leader

The Honorable Mitch McConnell  
Senate Republican Leader

---

**Dear President Biden, Secretary Becerra, Speaker Pelosi, Majority Leader Schumer, Leader McCarthy, Leader McConnell, America's Lawmakers, Patient Advocates, and Fellow Americans:**

We lead, fund, and count on the many small biotechnology companies that develop medicines for diseases\* that lack sufficient treatments and cause considerable suffering. The companies led by the executives among us employ 23,250 people in the US and collectively invest over \$17.7 billion/year in search of breakthroughs. We are currently testing 407 new and potentially life changing drug candidates in clinical trials, some of which build upon foundational NIH-funded research led by the academic researchers among us. The investors among us work at firms managing over \$185 billion of life science-focused capital that comes primarily from pension funds, families, universities, non-profits, and others who invest in drug development. Many of us are also patients and patient advocates, with loved ones who suffer from difficult diseases in need of better treatment options. We have dedicated ourselves to that effort.

Collectively we come together to defeat disease. Each drug in development is a complex, time consuming, and expensive scientific and medical undertaking. Most of the time we lose the battle. But we persist because the few projects that succeed will forever improve human health.

Our industry invests over \$160 billion in R&D each year. In the past decade it has created vaccines and treatments for Covid-19, treatments for cystic fibrosis and sickle cell disease, and cures for several cancers and hepatitis C. These successes are just a few examples of the many significant advances we are driving. Our efforts are reducing the burden and threat of diseases across the USA and around the globe.

It has become clear that we must also help our lawmakers understand the basic economic framework that inspires companies and investors to take the financial risk required to create new medicines. Called to action by the justifiable outrage of patients who cannot afford their out-of-pocket costs, some lawmakers have misdiagnosed the problem. They believe drug companies charge too much for their products. In response, they are proposing to enact laws that not only fall short of making drugs affordable to all patients but also defund our efforts to create better ones.

## The Right Goal

To be clear, we are concerned about the high and rising out-of-pocket costs that have made our medicines increasingly unaffordable to many patients. We, too, call for a solution to affordability. We don't invent drugs to have them placed out of the reach of people who need them.

Insurance makes it possible for Americans to afford today's medicines and collectively invest in tomorrow's, as is captured in [this short video](#). To solve the problem of affordability for patients, we must lower the amount that insurance plans can make patients pay out-of-pocket, redefining proper insurance by law, just as policymakers have appropriately outlawed discrimination on the basis of pre-existing conditions.

---

## The Wrong Policy

Instead, Congress is considering allowing the government to dictate the price that a company may charge for a novel drug with the threat of ruining the company financially with a 95% tax should the company refuse to accept the government's price.

Such draconian measures would immediately halt private funding of drug discovery and development. As an industry, we would no longer be able to infer what insurance plans might value and pay tomorrow from what they value and pay today, which is the premise of a market economy. Unpredictable government-dictated prices would supplant the current market-based framework that inspires biomedical R&D investment.

The investors among us would have to shift our investments toward areas still governed by markets, such as technology and consumer goods. Those companies with drug candidates in development would fail to raise more capital, making it pointless for them to spend existing dollars on ongoing research. The loss of hundreds of thousands of well-paying jobs would be swift, though it may take longer for the public to sense the loss of future treatments and cures.

Some may think NIH funding will be sufficient to fund continued R&D. The NIH is a crucial funder of the basic research that provides the ideas for what kinds of drugs might be possible.

Translating those ideas into actual medicines is almost entirely driven by the private sector and makes all that basic research worth funding in the first place. Some of us signing this letter are NIH funded academic researchers whose discoveries have had significant patient impact, and we affirm that the private sector has been and will continue to be essential for turning our ideas into medicines. The NIH and industry are parts [of one whole ecosystem](#), not a replacement for one another.

---

## What's in a Word?

Successful negotiations result in market-based prices based on competing alternatives – this negotiation already takes place between drug manufacturers and insurance companies, resulting in an average 50% reduction from drugs' list prices to their net prices.

True negotiation requires that both parties can walk away from the table. True negotiation is acceptable to all of us and spurs us to compete. True negotiation means that even if we don't get to the market first, our second and third place drugs can still secure some market share by competing on price.

The proposed introduction of a 95% tax penalty would allow The Center for Medicare and Medicaid Services (CMS) to simply dictate any drug's price. This is not true negotiation.

As proposed, the government would be able to keep a company from walking away from an unacceptably low price. This gives the American public the impression that they can have any drug that's been invented for any price, however low. Overlooked in that bargain is that investors and companies will stop investing in new programs, and we'll give up the medicines that haven't been invented yet.

Congress may not intend to dictate the price for every drug. But dictating the price of drugs covered by Medicare would defund R&D for diseases of aging, including Alzheimer's, osteoporosis, and cancer. Dictating prices for medicines priced above a certain threshold would defund R&D for rare diseases. Dictating prices for medicines that generate the most total revenue would defund R&D for our most difficult diseases, since those are the ones that require greater expected revenues to incentivize substantial R&D investment.

Dictating prices for drugs deemed less "valuable" to society sounds tempting, until one realizes that the math for estimating a drug's value is so nascent, imprecise, and controversial that it's easily biased to reflect the preferences of the practitioner. For example, a recent business plan competition demonstrated that [not a single project would be fundable](#) if future products could only be priced in accordance with the [over-simplified math](#) used in the UK and Canada. Furthermore, there is mounting evidence from health economics research that medicines offer greater societal value than is reflected by their prices.

---

## Better Solutions

We already have a functioning mechanism to drive down drug prices: drugs go generic. Because drugs go generic, what America spends on drugs has remained at roughly 10% of healthcare spending for decades, yet we have so many more effective and safer medicines today than in the 1970s.

---

Hospitals, long-term care facilities, and medical procedures do not go generic; those costs have only been climbing. We can keep ourselves from having to rely as much on hospitals in the future by inventing better medicines, which will then go generic. Society saves money, and we all lead healthier lives.

Preserving market-based incentives for drug R&D is how we get the medicines to achieve this goal. Heart transplants were first performed in 1967 and climbed in price by over 2,000% to cost \$1.4 million today. The heart failure drug amiloride helps avert the need for transplants and was approved in 1967; today it costs 26 cents/pill. We haven't solved heart failure, but we're working on it. So, there's hope for the people who need better heart failure medicines, but that hope requires continued investment in R&D.

America, and specifically CMS, can still save on drugs without sacrificing future treatments, cures, and vaccines. Certain drugs do not go generic even after their patents have expired, and CMS could save money by solving that particular market failure. Doing so would not reduce R&D incentives. [Members of industry](#) and others have proposed [a specific, actionable framework](#) for how this could work.

---

## Averting A Costly Error

It's true that replacing market-based pricing with non-market government-dictated prices will reduce healthcare spending in the short run (the Congressional Budget Office, which helps lawmakers determine what legislation may cost or save the government, uses a 10-year timeframe). But without new medicines, this policy will condemn America to spend far more on managing diseases in hospitals and long-term care facilities for decades to come.

The worst part is that it will take a long time to realize that we're not making progress like we used to. For example, antibiotic R&D has historically suffered from low investment incentives because the prices of antibiotics are so low. Today, we urgently need new antibiotics to combat the rise of resistant bacterial infections, but it will take years to remedy this gap in R&D even with proper incentives and funding. It's hard to appreciate what we don't have until we need it.

The advocates among us know this acutely, having worked with so many patients struggling to make it to the next breakthrough.

Where there are market failures, we should fix them. All drugs should go generic without undue delay. Americans should not suffer because their insurance burdens them with unaffordable out-of-pocket costs, whether they get their drugs through Medicare, their employer insurance, or on the public exchanges. Patients and policyholders should benefit from the savings insurers negotiate with drug companies, and drugs covered under Medicare Part B should be subject to the same competitive

market forces as those covered by Part D. Lawmakers should focus on these important, achievable, and bipartisan reforms for the benefit of all Americans.

In the meantime, the term “negotiation” must not be redefined to encompass the government dictating a price under threat of financial ruin. Were such a law to pass, capital would be immediately redirected away from biomedical R&D, with an immediate effect on biotechnology jobs and longer-term harm to patients and our national budget and security.

Some observers of the drug development ecosystem who propose different theories and models of how it works might contradict us. But the executives and investors among us write not as observers of biotech’s economic framework but as its actual elements and conductors; capital and incentives flow through our funds and our companies like electricity through a circuit. It is evident to us that replacing true negotiation with dictated prices would defund R&D, like flipping off a light switch.

Sincerely,

Peter Kolchinsky, Aoife Brennan, Alex Karnal, Jeremy Levin, Laura Shawver, Daphne Zohar, and Signatories to this Statement, listed below\*\*:

**Peter Kolchinsky, PhD**  
RA Capital Management, LP  
Boston, MA

**Aoife Brennan, MB, BCh, BAO, MRCPI**  
Synlogic Therapeutics  
Cambridge, MA

**Alex Karnal**  
Braidwell Management  
New York City, NY

**Jeremy Levin, D.Phil, MB BChir**  
Ovid Therapeutics  
New York City, NY

**Laura Shawver, PhD**  
Silverback Therapeutics  
Seattle, WA

**Daphne Zohar**  
PureTech Health  
Boston, MA

**Robert Langer, ScD**  
MIT  
Cambridge, MA

**Paul Hastings**  
Nkarta Therapeutics  
South San Francisco, CA

**Bob Nelsen**  
ARCH Venture  
Seattle, WA

**Jean Francois Formela, MD**  
Atlas Venture  
Boston, MA

**John Maraganore, PhD**  
Alynlam Pharmaceuticals  
Cambridge, MA

**Gunnar Esiason, MBA**  
Boomer Esiason Foundation  
New York, New York

**Ted W. Love, MD**  
Global Blood Therapeutics  
South San Francisco, CA

**Brook Byers**  
Kleiner Perkins  
Menlo Park, CA

**Siddhartha Mukherjee, MD Dphil**  
Columbia University  
New York, NY

**Arjun Goyal, MD**  
Vida Ventures  
Boston, MA

**Wendye Robbins**  
Blade Therapeutics  
South San Francisco, CA

**Ron Cohen, MD**  
Acorda Therapeutics  
Ardsley, NY

**Corey S. Goodman, PhD**  
venBio Partners  
San Francisco, CA

**Mark Murcko, PhD**  
Dewpoint Therapeutics  
Boston, MA

**Kush M Parmar, MD, PhD**  
5AM Ventures  
Boston, MA

**Akiko Iwasaki**  
Yale University  
New Haven, CT

**Nina Kjellson**  
Canaan Partners  
San Francisco, CA

**Rajeev Shah**  
RA Capital Management, LP  
Boston, MA

**J. Tyler Martin, MD**  
Adjuvance Technologies  
Lincoln, NE

**Robert Ang**  
Vor BioPharma  
Cambridge, MA

**D.A. Wallach**  
Time BioVentures  
Los Angeles, CA

**Jeffrey L Cleland, PhD**  
Ashvattha Therapeutics  
Redwood City, CA

**Jake Becraft, PhD**  
Strand Therapeutics Inc  
Cambridge, MA

**Peter A. Thompson, MD**  
OrbiMed Advisors  
New York, NY

**James McArthur, PhD**  
PepGen Inc  
Cambridge, MA

**Robert D. Schultz**  
Satsuma Pharmaceuticals, Inc.  
Durham, NC

**Jeffrey Bird, MD, PhD**  
Bluebird Ventures  
Palo Alto, California

**Troy Wilson, PhD, JD**  
Kura Oncology  
San Diego, CA

**Peter Bisgaard**  
Pivotal Life Sciences  
San Francisco, CA

**John A. Scarlett, MD**  
Geron Corporation  
Foster City, CA

**Todd Harris**  
Tyra Biosciences  
Carlsbad, CA

**Paul Bolno, MD**  
Wave Life Sciences  
Cambridge, MA

**Cedric Francois, MD, PhD**  
Apellis Pharmaceuticals, Inc.  
Waltham, MA

**Marc de Garidel**  
CinCor  
Boston, MA

**Andreas Wicki**  
HBM Healthcare Investments AG  
Zug, Switzerland

**Jill C. Milne, PhD**  
Catabasis Pharmaceuticals  
Boston, MA

**Jeffrey A. Leerink**  
SVB Leerink  
Boston, MA

**Jay Venkatesan, MD**  
Angion  
Uniondale, NY

**Nicholas Oo**  
Invus  
New York, NY

**Stephen J. Hoffman, PhD, MD**  
Apic-Bio, Inc.  
Cambridge, MA

**David A. Katz, PhD**  
Sparrow Pharmaceuticals  
Portland, OR

**Joseph Healey**  
HealthCor Management  
New York, NY

**Joshua Resnick, MD**  
RA Capital  
Boston, MA

**Jeff Albers**  
Blueprint Medicines  
Cambridge, MA

**Agustin Mohedas, PhD**  
Janus Henderson Investors  
Denver, CO

**Blake Wise**  
Novome Biotechnologies  
South San Francisco, CA

**David-Alexandre C. Gros, MD**  
Eledon Pharmaceuticals  
Irvine, CA

**Larry Feinberg**  
Oracle Partners L.P.  
Greenwich, CT

**Ashley Dombkowski, PhD**  
Alladapt Immunotherapeutics, Inc  
Menlo Park, CA

**Alain D. Baron, MD**  
Escient Pharmaceuticals  
San Diego, CA

**Andrew N. Schiff, MD**  
Aisling Capital  
New York, NY

**Michael R. Hayden, MBChB, PhD**  
Prilenia Therapeutics  
Herzaliya, Israel

**Amit D. Munshi**  
Arena Pharmaceuticals Inc  
San Diego, CA

**Melinssa McCracken, PhD**  
Nextech Invest  
Boston, MA

**Timothy M Shannon, MD**  
Canaan Partners  
Westport, CT

**John Kollins**  
Satsuma Pharmaceuticals, Inc.  
South San Francisco, CA

**Ed Mascioli**  
EMMD LLC  
Boston, MA

**Nancy A. Thornberry**  
Kallyope  
New York, NY

**Amy Burroughs**  
Cleave Therapeutics  
San Francisco, CA

**Alex Virgilio**  
Asymmetry Capital Management  
San Francisco, CA

**Frank Watanabe**  
Arcutis Biotherapeutics  
Westlake Village, CA

**Sarah Boyce**  
Avidity Bioscience  
San Diego, CA

**Brian Halak, PhD**  
Domain Associates  
Princeton, NJ

**Ken Drazan**  
Arsenal Biosciences  
South San Francisco, CA

**David Sable, MD**  
Special Situations Life Sciences Fund  
New York, NY

**Nassim Usman, PhD**  
Catalyst Biosciences  
South San Francisco, CA

**Jon Edwards, PhD**  
Red Tree Venture Capital  
Menlo Park, CA

**Sean Jeffries, PhD**  
Design Therapeutics  
Carlsbad, CA

**Jak Knowles**  
Affini-T Therapeutics  
Boston, MA

**Yishai Zohar**  
Gelesis Inc  
Boston, MA

**Dr. Vipin Garg**  
Altimune, Inc.  
Gaithersburg, MD

**Dan Becker, MD, PhD**  
Access Biotechnology  
New York, NY

**Sadik H. Kassim, PhD**  
Vor Bio  
Cambridge, MA

**James A. Geraghty**  
Fulcrum Therapeutics  
Cambridge, MA

**Doug Crawford**  
Mission BioCapital  
San Francisco, CA

**Eric Dube, PhD**  
Travere Therapeutics  
San Diego, CA

**Gregory J. Flesher**  
Reneo Pharmaceuticals, Inc.  
Irvine, CA

**Matt Eckler**  
Arrowmark Partners  
Denver, CO

**Scott Clarke**  
Ambagon Therapeutics  
San Francisco, CA

**Andy Schwab**  
5AM Ventures  
San Francisco, CA

**Vikram Khanna**  
Ikarian Capital  
Dallas, TX

**Stephen Dilly M.B.B.S., Ph.D**  
Sierra Oncology  
San Francisco, CA

**Cris Montero, PhD**  
RA Capital Management, LP  
Boston, MA

**Todd Foley**  
MPM Capital  
Cambridge, MA

**Kenneth I. Moch**  
Euclidean Life Science Advisors  
Chapel Hill, NC

**Michael Broxson**  
Q32 Bio  
Cambridge, MA

**Arthur Tzianabos, PhD**  
Homology Medicines  
Bedford, MA

**Bernat Olle**  
Vedanta Biosciences  
Cambridge, MA

**Stephen J. Farr PhD**  
Zogenix, Inc.  
Emeryville, CA

**Pieter Boelhouwer JD**  
RA Capital Management, LP  
Boston, MA

**Harith Rajagoplan MD, PhD**  
Fractyl Health  
Lexington, MA

**Patrick Heron**  
Frazier Life Sciences  
Menlo Park, CA

**Zach Scheiner, PhD**  
RA Capital Management, LP  
Boston, MA

**Michael D. Clayman, MD**  
Flexion Therapeutics, Inc.  
Burlington, MA

**Jeffrey M. Solomon**  
Cowen Inc.  
New York, NY

**Jyoti Chauhan**  
Landos Biopharma Inc.  
Blacksburg, VA

**Anurag Kondapalli**  
RA Capital Management, LP  
Boston, MA

**Jake Simson, PhD**  
RA Capital Management, LP  
Boston, MA

**Marina Udier**  
Nouscom AG  
Basel, Switzerland

**JP Sommandossi**  
Atea Pharmaceuticals  
Boston, MA

**Fredrik Wiklund**  
Bright Peak Therapeutics  
San Diego, CA

**Tomer Kariv**  
Pontifax  
Israel/UK

**Laurie Halloran, BSN, MS**  
Halloran Consulting Group, Inc.  
Boston, MA

**Adam Rosenberg**  
Ambagon Therapeutics  
San Francisco, CA

**Bob Ward**  
OncoSec Immunotherapies  
Princeton, NJ

**Andrew Levin, MD, PhD**  
RA Capital Management, LP  
Boston, MA

**Maria Koehler MD, PhD**  
Repare Therapeutics  
Cambridge, MA

**Mark Corrigan MD**  
Exacis Biotherapeutics  
Boston, MA

**Laura Tadvalkar, PhD**  
RA Capital Management, LP  
Boston, MA

**James Mackay**  
Aristea Therapeutics  
San Diego, CA

**Zachary Hornby**  
Boundless Bio, Inc.  
San Diego, CA

**Matthew Hammond, PhD**  
RA Capital Management, LP  
Boston, MA

**Ali Behbahani**  
New Enterprise Associates  
Washington DC

**Branden B. Muhl**  
B Group Capital  
Dallas, TX

**Paul Sekhri**  
eGenesis, Inc.  
New York, NY

**Adi Hoess**  
Affimed NV  
Heidelberg, Germany

**Peter Greenleaf**  
Aurinia Pharmaceuticals  
Rockville, MD

**Michael Kauffman MD, PhD**  
Verastem  
Newton, MA

**Rosana Kapeller**  
ROME Therapeutics  
Cambridge, MA

**Zach Collins**  
Mission Biocapital  
San Francisco, CA

**Llew Keltner, MD, PhD**  
Light Sciences Oncology  
Portland, OR

**Christoph Westphal**  
Longwood Fund  
Boston, MA

**Roger J Pomerantz MD, FACP**  
ContraFect  
New York, NY

**Francesco Draetta**  
Omega Funds  
Boston, MA

**Bob Linke**  
Osmol Therapeutics, Inc.  
New Haven, CT

**Taylor Schreiber MD, PhD**  
Shattuck Labs, Inc.  
Durham, NC



**H. Stewart Parker**  
Parker BioConsulting  
Chapel Hill NC

**Russell Cox**  
Epirium Bio  
San Diego, CA

**Derek DiRocco, PhD**  
RA Capital Management, LP  
Boston, MA

**Jeremy P. Springhorn, PhD**  
Nido Biosciences  
Cambridge, MA

**Tess Cameron**  
RA Capital Management, LP  
Boston, MA

**Laura Stoppel, PhD**  
RA Capital Management, LP  
Boston, MA

**Pratik Shah, PhD**  
Design Therapeutics  
San Diego, CA

**Brad Loncar**  
Loncar Investments  
Lenexa, KS

**Dennis Purcell**  
Aisling Capital  
New York City, NY

**Reza Halse, PhD**  
RA Capital Management, LP  
Boston, MA

**Adam Keeney**  
NodThera  
Lexington, MA

**Jeremy Bender, PhD**  
Day One Biopharmaceuticals, Inc.  
South San Francisco, CA

**Jeffrey H. Knapp**  
DNAtrix, Inc.  
Houston, TX

**Richard W. Pascoe**  
Histogen Inc.  
San Diego, CA

**John P. Butler**  
Akebia Therapeutics  
Cambridge, MA

**Erich Scheller, PhD**  
RA Capital Management, LP  
Boston, MA

**David H. Crean**  
Coast BioVentures  
San Diego, CA

**Peter Strumph**  
Parvus Therapeutics  
San Francisco, CA

**Scott M. Rocklage**  
5AM Ventures  
Boston, MA

**Scott Kellen**  
DiaMedica Therapeutics Inc.  
Minneapolis, MN

**Jason Gardner**  
Magenta Therapeutics  
Cambridge, MA

**Armando Anido**  
Zynerba Pharmaceuticals  
Devon, PA

**Walter H. Moos**  
Pandect Bioventures  
South San Francisco, CA

**John Tucker**  
scPharma  
Burlington, MA

**Nancy Simonian**  
Syros Pharmaceuticals  
Cambridge, MA

**Kate Moreau, PhD**  
RA Capital Management, LP  
Boston, MA

**Mike Derkacz**  
Braeburn  
Plymouth Meeting, PA

**Douglas Ingram**  
Sarepta Therapeutics  
Cambridge, MA

**James N. Campbell, MD, FAANS**  
Centrexion Therapeutics  
Baltimore, MD

**Joseph Edelman**  
Perceptive Advisors  
New York, NY

**Matt Cohen, PhD**  
Osage University Partners, LP  
Bala Cynwyd, PA

**Jon Soderstrom, PhD**  
Yale University  
New Haven, CT

**Kevin Kimberlin**  
Spencer Trask & Co  
Greenwich, CT

**Bassil Dahiyat**  
Xencor  
Monrovia, CA

**John F. Crowley**  
Amicus Therapeutics, Inc.  
Philadelphia, PA

**Joshua T. Brumm**  
Dyne Therapeutics  
Waltham, MA

**Sandip Agarwala**  
Longitude Capital  
Greenwich, CT

**Randy Mitchell**  
Alyeska Investment Group  
Chicago, IL

**Ronald C Renaud Jr.**  
Translate Bio  
Lexington, MA

**Travis Wilson**  
Gurnet Point  
Cambridge MA

**Jeff Kindler**  
Centrexion Therapeutics  
Boston, MA

**Jason Lin**  
TwoThree Capital  
Toronto, ON

**Jason Bhardwaj**  
Follica, Inc.  
Boston, MA

**David de Graaf, PhD**  
Abcuro, Inc.  
Newton, MA

**John Neis**  
Venture Investors  
Madison, WI

**Wesley M. Jackson**  
Valitor  
Berkeley, CA

**Rich Aldrich**  
Longwood Fund  
Boston, MA

**Peter Rubin**  
No Patient Left Behind (NPLB)  
Washington, DC

**Adam Simpson**  
Icosavax, Inc.  
Seattle, WA

**Douglas M Fambrough**  
Dicerna Pharmaceuticals, Inc.  
Lexington, MA

**Shuo Zhang**  
AuGC Partners  
Belmont, CA

**Keith Murphy**  
Viscient Biosciences  
San Diego, CA

**Neil Warma**  
I-Mab Biopharma U.S.  
San Diego, CA

**Steve Elms**  
Aisling Capital  
New York, NY

**Jeffrey Herz, PhD**  
Algomedix, Inc.  
Mill Creek, WA

**Jeb Keiper**  
Nimbus Therapeutics  
Cambridge, MA

**Brent Ahrens**  
Canaan Partners  
Menlo Park, CA

**Wendell Wierenga, PhD**  
Chairman, Crinetics  
San Diego, CA

**Ken Takanashi**  
SNBL Ltd.  
Tokyo, Japan

**Misha Petkevich, DPhil**  
V2M Capital LLC  
West Palm Beach, FL

**Josh Mandel-Brehm**  
CAMP4 Therapeutics  
Cambridge, MA

**Chen Yu, MD, MBA**  
TCG Crossover  
Palo Alto, CA

**Jason Bonadio, MD**  
Alera Partners  
Greenwich, CT

**David Socks**  
HilleVax, Inc.  
Boston, MA

**Aaron Royston**  
venBio Partners  
San Francisco, CA

**Dillon Hoover**  
CASTLEARK MANAGEMENT, LLC  
Chicago, IL

**Art Pappas**  
Pappas Capital, LLC  
Research Triangle Park, NC

**Carmine Stengone**  
Pipeline Therapeutics  
San Diego, CA

**Laura A Brege**  
Acadia Pharmaceuticals  
San Diego, CA

**Jonathan Rourke**  
MitraSpan  
Belmont, MA

**Joseph Leveque, MD**  
Mirati Therapeutics  
San Diego, CA

**Evan Markegard**  
AuGC Partners LLC  
Belmont, CA

**David J. Woodhouse, PhD**  
NGM Biopharmaceuticals, Inc.  
South San Francisco, CA

**Rachael Nokes**  
scPharmaceuticals Inc.  
Burlington, MA

**Joseph Sarret**  
CohBar, Inc.  
Menlo Park, CA

**Bharat Chowrira, PhD, JD**  
PureTech Health  
Boston, MA

**Scott Harris**  
Cleave Therapeutics, Inc.  
San Francisco, CA

**Pearl Freier**  
Cambridge BioPartners, Inc.  
Cambridge, MA

**Joao Siffert**  
Design Therapeutics  
San Diego, CA

**Rick Pauls**  
DiaMedica Therapeutics  
Minneapolis, MN

**Catherine Stehman-Breen, MD**  
Chroma Medicine  
Cambridge, MA

**Michael Hassman**  
scPharmaceuticals Inc.  
Burlington, MA

**Joseph Bolen, PhD**  
PureTech Health  
Boston, MA

**Jacob Chacko, MD**  
ORIC Pharmaceuticals  
South San Francisco, CA

**Catherine Pearce, DHSc, MBA**  
CinCor Pharma Inc.  
Cincinnati, OH

**Justin R. Thompson**  
CinCor Pharma, Inc.  
Cincinnati, OH

**Albert Seymour, PhD**  
Homology Medicines, Inc.  
Bedford, MA

**Alyssa Larson, PhD**  
RA Capital Management, LP  
Boston, MA

**Neil Exter**  
Third Rock Ventures  
Boston, MA

**Chip Clark**  
Genocea Biosciences, Inc.  
Cambridge, MA

**William E. Rote, PhD**  
Travere Therapeutics  
San Diego, CA

**June H. Lee, MD**  
Esker Therapeutics  
San Francisco, CA

**Jonathan Piazza**  
Silverback Therapeutics  
Seattle, WA

**Cristina GhenoIU, PhD**  
RA Capital Management, LP  
Boston, MA

**Adrian Gottschalk**  
Foghorn Therapeutics  
Cambridge, MA

**Will Brown**  
Altimune, Inc.  
Gaithersburg, Maryland

**Daniel E. Rosan**  
Synlogic Therapeutics  
Cambridge, MA

**Adrian (Ad) Rawcliffe**  
Adaptimmune  
Philadelphia, PA

**Emily Drabant Conley, PhD**  
Federation Bio  
South San Francisco, CA

**Steven Burke, MD**  
Akebia Therapeutics  
Cambridge, MA

**Richard Gaster, MD, PhD**  
venBio Partners  
San Francisco, CA

**Daniel Bensen**  
Tyra Biosciences, Inc.  
Carlsbad, CA

**John L. LaMattina**  
PureTech Hrealth  
Stonington, CT

**Nathaniel Brooks Horwitz**  
RA Capital Management, LP  
Boston, MA

**Jason Rhodes**  
Atlas Venture  
Boston, MA

**Lee D. Cooper**  
Leaps by Bayer  
Cambridge, MA

**Otello Stampacchia**  
Omega Funds  
Boston, MA

**Ankit Mahadevia, MD**  
Spero Therapeutics  
Cambridge, MA

**Brian Rosenberger**  
Zynerba Pharmaceuticals  
Devon, PA

**Kristina Burow**  
ARCH Venture Partners  
Chicago, IL

**Philip Astley-Sparke**  
Replimune Inc  
Boston, MA

**Faheem Hasnain**  
Gossamer Bio  
San Diego, CA

**Timothy P. Walbert**  
Horizon Therapeutics  
Deerfield, IL

**Stan Wang, MD, PhD**  
Thymune Therapeutics  
Cambridge, MA

**Rohan Palekar**  
89bio Inc.  
San Francisco, CA

**Nancy Lurker**  
EyePoint Pharmaceuticals  
Watertown, MA

**Ron Hunt**  
New Leaf Venture Partners  
New York, NY

**Ivor Royston, MD**  
Viracta Therapeutics  
Cardiff, CA

**Peter Parker**  
Mission BioCapital  
Cambridge, MA

**Todd Krueger**  
AOBiome Therapeutics  
Cambridge, MA

**Paulina Hill**  
Omega Funds  
Boston, MA

**Ari Zweiman**  
683 Capital Management LLC  
New York, NY

**Mark Leuchtenberger**  
Aleta Biotherapeutics  
Natick, MA

**Mike Sherman**  
Chimerix  
Durham, North Carolina

**CJ Sylvester**  
Manulife  
Boston, MA

**Ephraim Heller**  
SynAgile Corporation  
Wilson, WY

**Rebecca Lucia, CFA**  
5AM Ventures  
San Francisco, CA

**W. Eddie Martucci, PhD**  
Akili Interactive Labs  
Boston, MA

**Fouad Azzam, PhD**  
Life Sciences Partners  
Waltham, MA

**Habib Dable**  
Accelaron Pharma  
Cambridge, MA

**David V. Goeddel, PhD**  
Tenaya Therapeutics  
San Francisco, CA

**Steven Gillis**  
ARCH Venture Partners  
Seattle, WA

**Carl L. Hansen, PhD**  
AbCellera  
Vancouver, BC Canada

**Adam M. Koppel**  
Bain Capital Life Sciences  
Boston, MA

**Raju Kucherlapati**  
Harvard Medical School  
Boston, MA

**Jonathan Kipnis**  
Washington University in St. Louis  
St. Louis, MO

**Brian S. Kim, MD, MTR, FAAD**  
Washington University School of  
Medicine; St. Louis, MO

**Norbert Bischofberger**  
Kronos Bio  
San Mateo, CA

**Angie You, PhD**  
Amunix Pharmaceuticals  
South San Francisco, CA

**Kevin Bitterman**  
Atlas Venture  
Cambridge, MA

**Paul Johnson**  
Braeburn  
Plymouth Meeting, PA

**Mike Powell**  
Omega Funds  
Boston, MA

**Fred Aslan, MD**  
Artiva Biosciences  
San Diego, CA

**Michael A. Schrader**  
Vaxess Technologies, Inc.  
Cambridge, MA

**David Grayzel, MD**  
Atlas Venture  
Boston, MA

**Kris Jenner**  
Rock Springs Capital  
Baltimore, MD

**David Kroin**  
Deep Track Capital  
Greenwich, CT

**Vicente Anido, PhD**  
Aerie Pharmaceuticals, Inc  
Durham, NC

**Aaron Davis**  
Boxer Capital  
San Diego, CA

**Evan Loh, MD**  
Paratek Pharmaceuticals  
Boston, MA

**Stephen Hurly**  
LAVA Therapeutics  
Philadelphia, PA

**Jerry Cahill**  
Boomer Esiason Foundation  
New York, NY

**Dave Madden**  
River 2 and 3 Renal Corps  
New York, NY

**Robert L. Hudkins**  
Tyra Bioscience  
Carlsbad, CA

**Valerie Daggett, PhD**  
AltPep  
Seattle, WA

**Steve Dickman**  
CBT Advisors  
Cambridge, MA

**Ray Debbane**  
Invus  
New York, NY

**Philippe Amouyal**  
Invus  
Miami, FL

**Khalil Barrage**  
Invus  
New York, NY

**Bertrand Georges**  
Altimune Inc.  
Gaithersburg, MD

**Thomas E Darcy**  
Viracta Therapeutics, Inc.  
Cardiff, CA

**Sen Sundaram**  
Terns Pharmaceuticals  
Foster City, CA

**Greg Mayes**  
Antios Therapeutics  
Mendham, NJ

**Barry Quart, PharmD**  
Heron Therapeutics  
San Diego, CA

**Clay B. Thorp**  
Hatteras Venture Partners  
Durham, NC

**David Hirsch**  
Longitude Capital  
Boston, MA

**Evan Greif**  
Bain Capital Life Sciences  
Boston, MA

**Jeffrey Bluestone, PhD**  
Sonoma Biotherapeutics  
South San Francisco, CA

**Adam Muzikant, PhD**  
Flexion Therapeutics  
Burlington, MA

**Emily Schaller**  
Rock CF Foundation  
Detroit, MI

**William S. Slattery**  
Deerfield Management  
New York, NY

**Daniel Vitt**  
Immunic Therapeutics  
New York City, NY

**Khrystal K Davis, JD**  
Texas Rare Alliance  
Austin, TX

**Jim Sullivan, PhD**  
Vanqua Bio  
Chicago, IL

**Hillary Theakston**  
Clarity  
San Diego, CA

**Noah L. Rosenberg, MD**  
Travere Therapeutics  
San Diego, CA

**Galya Blachman**  
5AM Ventures  
San Francisco, CA

**Deborah Palestrant**  
5AM Ventures  
Boston, MA

**Barry Labinger**  
Checkmate Pharmaceuticals  
Cambridge, MA

**Roderick Wong, MD**  
RTW Investments  
New York, NY

**Vasudev Bailey, PhD**  
Artis Ventures  
San Francisco

**Chris Garabedian**  
Perceptive Advisors  
Boston, MA

**Jose Ochoa**  
Altimmune  
Gaithersburg, MD

**Lloyd M. Segal**  
Repare Therapeutics Inc.  
Cambridge, MA

**Ansbert Gadicke**  
MPM Capital  
Cambridge, MA

**Robert Adelman, MD**  
venBio  
San Francisco

**Michael Nolan**  
Freenome  
South San Francisco, CA

**Peter Wirth**  
Quan Capital Management  
Boston, MA

**Michelle Ho**  
5AM Ventures  
San Francisco, CA

**Bong Koh, MD**  
Venrock  
New York, NY

**Bruce Booth**  
Atlas Venture  
Boston MA

**Albert Gianchetti**  
XyloCor Therapeutics  
Malvern, PA

**Peter Smith**  
Remix Therapeutics  
Cambridge, MA

**John E. Osborn**  
BioVentures Investors  
Wellesley, MA

**Sean McCarthy**  
CytomX Therapeutics  
South San Francisco, CA

**Jonathan Lim, MD**  
Erasca  
San Diego, CA

**Josh Richardson**  
Longitude Capital  
Boston, MA

**Kevin Pyun**  
Dellora Investments LP  
Greenwich, CT

**Pascal Touchon**  
Atara Biotherapeutics  
San Francisco, CA

**Robert Blazej, PhD**  
MBC Biolabs  
San Francisco, CA

**Samuel L Murphy, PhD**  
Salubris Biotherapeutics  
Cambridge, MA

**Aaron Hakim, MD**  
Deep Track Capital  
Boston, MA

**Mark Simon**  
Torreya Partners  
New York, NY

**James Brush, MD**  
Frazier Healthcare Partners  
Menlo Park, CA

**Thomas Malley**  
Mossrock Capital, LLC  
Englewood, CO

**Douglas Fisher, MD**  
InterWest Partners  
Menlo Park, CA

**Daniel Koller**  
BB Biotech AG  
Schaffhausen, Switzerland

**Sanjiv Patel**  
Relay Therapeutics  
Boston, MA

**Ryan Lane**  
Empery Asset Management LP  
New York, NY

**Sandy Mong MD**  
Atlas Venture  
Boston, MA

**James Blair**  
Domain Associates LLC  
Princeton, NJ

**Joanne Kotz, PhD**  
Jnana Therapeutics  
Boston, MA

**Allen Conger**  
NeuroMedica  
Mt. Pleasant, SC

**Michael Keyoung, MD, PhD**  
CBC Group  
New York, NY

**Seth Rotberg, MNM**  
Our Odyssey  
Chicago, IL

**Michael S. Weiss**  
TG Therapeutics  
Boca Raton, FL

**Bala Venkataraman**  
Avego Management  
Alpharetta, GA

**Stan Erck**  
Novavax  
Gaithersburg, MD

**Harris Weber**  
Bain Capital  
Boston, MA

**Gerard Smith**  
Deep Track Capital  
Greenwich, CT

**Michael Gladstone**  
Atlas Venture  
Cambridge, MA

**Axel Hoos**  
Scorpion Therapeutics  
Boston, MA

**Vincent S. Mosca**  
Ditch Plains Capital Management  
Manhasset, NY

**Colin Wang**  
6 Dimensions Capital  
Cambridge, MA

**Patrick Nosker, PhD**  
Affinity Asset Advisors, LLC  
New York, NY

**Fred Dotzler**  
De Novo Ventures  
Saratoga, CA

**Dan Janney**  
Alta Partners  
San Francisco, CA

**Michael J. Hearle**  
Clough Capital Partners  
Boston, MA

**Doug Roeder**  
Delphi Ventures  
San Mateo, CA

**David Allison**  
5AM Ventures  
San Francisco, CA

**Wende Hutton**  
Canaan Partners  
Menlo Park CA

**Robert F. Johnston**  
Johnston Associates, Inc.  
South Hamilton, MA

**Albert Cha**  
Frazier Healthcare Partners  
Menlo Park, CA

**Marc W. Elia**  
M28 Capital Management  
Stamford, CT

**Thomas A. Romero**  
Capital Research Partners & Co.  
Norwalk, CT

**Laurence Blumberg, MD**  
Arch Oncology  
Brisbane, CA

**Bryan Roberts**  
Venrock  
Palo Alto, CA

**Jonathan Root, MD**  
U.S. Venture Partners  
Menlo Park, CA

**Gary Stern**  
Eagle Health Investments  
Greenwich, CT

**Lazar Dimitrov, PhD**  
Day One Biopharmaceuticals  
South San Francisco, CA

**Andrew Oberwager MD**  
Machaon Capital Managemnt LP  
Stamford, CT

**Benjamin Young**  
Gray's Creek Capital Partners  
Westport, CT

**Julie Papanek Grant**  
Canaan  
Menlo Park, CA

**Owen Smith, MSc, CPFA**  
4BIO Capital  
London, UK

**Dr. Michael Fischer**  
Medical Strategy - Investmentmanager  
Munich, Germany

**Dmitry A. Kuzmin, PhD ,FRSB**  
4BIO Capital LLP  
London, U.K.

**Matt Renna**  
Westfield Capital Management  
Boston, MA

**Thilo Schroeder**  
Nextech Invest  
Zurich, CH

**Torbjorn Bjerke, MD**  
Arctic Asset Management  
Stockholm, Sweden

**Nicole Vitullo**  
Domain Associates, LLC  
Princeton, NJ

**Chris Varma, PhD**  
Frontier Medicines  
South San Francisco, CA

**Francis Parnell, MD**  
Parnell Pharmaceuticals Inc  
San Rafael, CA

**James Sapirstein**  
AzurRx BioPharma  
Boca Raton, FL

**Laurie Stelzer**  
Arena Pharmaceuticals  
San Diego, CA

**Bill Newell**  
Sutro Biopharma, Inc.  
South San Francisco, CA

**Barry Simon, M.D.**  
ImmunityBio  
San Diego, CA

**Avanish Vellanki**  
Rain Therapeutics  
Newark, CA

**Michael Stocum**  
Bantam Pharmaceutical  
Research Triangle Park, NC

**Angelos M. Stergiou, MD, ScD hc**  
SELLAS Life Sciences Group  
New York City, NY

**Micah J. Benson, PhD**  
KSQ Therapeutics  
Cambridge, MA

**Parag G. Mehta**  
Aveta Biomics  
Bedford, MA

**John Bencich**  
Achieve Life Sciences  
Seattle, WA

**Imran Alibhai, PhD**  
Tvardi Therapeutics  
Houston, TX

**Katie Kerfoot**  
Omega Funds  
Boston, MA

**Alicia Yin**  
6 Dimensions Capital  
Palo Alto, CA

**Walter T. Dec, CFA**  
Dec Family Ventures, LLC  
Tewksbury, NJ

**Jay M. Short, PhD**  
BioAtla, Inc.  
San Diego, CA

**Thomas P. Mathers**  
Allievex Corporation  
Marblehead, MA

**Rami Levin**  
Saniona  
Waltham, MA

**Jigar Raythatha**  
Constellation Pharmaceuticals, Inc.  
Cambridge, MA

**Ying Huang, PhD**  
Legend Biotech  
Somerset, NJ

**Sujal Shah**  
CymaBay Therapeutics  
Newark, CA

**Jim Fickenscher**  
Zynerba Pharmaceuticals, Inc.  
Devon, PA

**Rob Shaffer, PhD**  
Enable Therapeutics  
Boston, MA

**Andrew Booth**  
AbCellera  
Vancouver, Canada

**Adam J. Fein, PhD**  
Drug Channels Institute  
Philadelphia, PA

**Arthur J. Hiller**  
Amasa Therapeutics, Inc.  
Boston, MA

**Brad R. Balter, CFA**  
Bain Capital Life Sciences  
Boston, MA

**Brian Bloom**  
Bloom Burton & Co.  
Toronto, ON

**Mark J. Enyedy**  
ImmunoGen, Inc.  
Waltham, MA

**Jeff Livingstone**  
Igia Pharmaceuticals  
Franklin, MA

**Charles M. Baum, MD, PhD**  
Mirati Therapeutics Inc  
San Diego, CA

**Rick E. Winningham**  
Theravance Biopharma  
South San Francisco, CA

**Standish Fleming**  
Forward Ventures  
San Deigo, CA

**Dr. Johannes Fruehauf**  
Mission BioCapital  
Cambridge, MA

**Amir Kalali, MD**  
ATAI Life Sciences  
San Diego, CA

**Frank Lee**  
Forma Therapeutics  
Watertown, MA

**Paul M.K. Weiss, PhD**  
Venture Investors, LLC  
Madison, WI

**Sunny Reddy**  
Aisling Capital  
New York, NY

**Sameh Ahsan**  
Exome Asset Management  
New York, NY

**Michael Raab**  
Ardelyx, Inc.  
Fremont, CA

**Mark Manfredi**  
Ikena Oncology  
Boston, MA

**Christoph Broja**  
Gurnet Point Capital  
Boston, MA

**Derek Lowe**  
In the Pipeline  
Cambridge, MA

Julie Anne Smith  
ESCAPE Bio  
South San Francisco, CA

Avinash Amin, MD  
Madryn Asset Management, LP  
New York, NY

William O. Robb  
Madryn Asset Management  
New York, NY

**\* Diseases that companies affiliated with signatories are working to prevent, treat, or cure:**

ADHD, ALS, Alzheimer's, Amyloid diseases, Anemia, ARDS, Autism, Autoimmune Disorders, Benign Prostatic Hyperplasia, Blindness, Breast Cancer, Chemotherapy Induced Peripheral Neuropathy and Chemotherapy Induced Cognitive Impairment, Chronic Hepatitis B, Chronic Lymphocytic Leukemia, Chronic Pain, Cognitive Injuries, Colorectal Cancer, Complement Disorders, COVID, Dementia, DM1, DMD, Enteric Hyperoxaluria, Fragile X syndrome, FSGS, FSHD, Gout, Heart Failure, Huntington's Diseases, Idiopathic Pulmonary Fibrosis, IgA nephropathy, Infectious Disease, Inflammatory Bowel Disease, Influenza, Long COVID, Lung Cancer, Lupus, Major Depressive Disorder, Melanoma, MLD, MPS2, Multiple Sclerosis, NASH, NMOSD, Non-Hodgkin Lymphoma, Obesity, Opioid Use Disorder, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Parkinson's Psychosis, Pediatric Leukemias, Pediatric low grade glioma, PKU, Post-surgical Pain, Primary Biliary Cholangitis, Prostate Cancer, Pulmonary Arterial Hypertension, Rare Epilepsies, Renal Cancer, Retinal eye diseases, Rhetts Syndrome, Stroke, Type 1 Diabetes, Type 2 Diabetes, Uterine Cancer, and many other diseases.

*\*\*The appended signatures do not necessarily reflect the policy or position of any agency, organization, employer, or company with which the signatories are affiliated.*

CC: House Energy and Commerce Committee Chair Pallone and Ranking Member McMorris Rodgers  
House Ways and Means Committee Chair Neal and Ranking Member Brady  
Senate Finance Chair Wyden and Ranking Member Crapo  
Senate Health, Education, Labor, and Pensions Chair Murray and Ranking Member Burr

To join us in signing this letter, [please click here](#) and you'll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won't show up right away.